Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.6
4.9
Journals
Marine Drugs
Special Issues
Bioactive Products from Marine Cyanobacteria and Their Potential Therapeutic Applications...
share announcement

Bioactive Products from Marine Cyanobacteria and Their Potential Therapeutic Applications 2022

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: closed (27 September 2022) | Viewed by 10915

Special Issue Editor

Dr. Michele R. Prinsep

E-Mail Website
Guest Editor
Department of Chemistry, The University of Waikato, Te Whare Wānanga o Waikato, Gate 1 Knighton Road, Private Bag 3105, Hamilton 3240, New Zealand
Interests: natural products chemistry; application of spectral methods to structural determination; biologically active compounds and structure-activity relationships; chemical ecology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cyanobacteria (blue-green algae) are an ancient and successful group of organisms, found in a wide range of marine and freshwater habitats and in conditions as extreme as the cold of Antarctica to the heat of volcanic regions. They have proven to be an excellent source of secondary metabolites, many of which possess biological activity. The most common class of compounds found in cyanobacteria are oligopeptides (predominantly cyclic peptides), of which many contain unique or unusual amino acids. These are synthesised by non-ribosomal peptide synthetases. Some of the other compound classes that have been isolated from cyanobacteria include terpenes and alkaloids.

Many of the natural products produced by cyanobacteria may be ecologically significant and some of the toxic metabolites are a human health concern, especially when present in recreational water bodies or fisheries. Cyanobacteria often have the means to produce many more metabolites than are actually expressed, so an understanding of biosynthesis and genetics in these organisms is vitally important.

There is considerable overlap between metabolites produced by terrestrial and marine cyanobacteria, however, this Special Issue will only include studies concerning freshwater cyanobacteria if there is obvious relevance to marine species. We look forward to receiving your contributions.

Dr. Michele R. Prinsep
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cyanobacteria
  • blue-green algae
  • oligopeptide
  • noribosomal peptide sythetase
  • biological activity
  • toxicity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 2222 KiB  
Article
Isolation and Biological Activity of Iezoside and Iezoside B, SERCA Inhibitors from Floridian Marine Cyanobacteria
by Sofia Kokkaliari, Danmeng Luo, Valerie J. Paul and Hendrik Luesch
Mar. Drugs 2023, 21(7), 378; https://doi.org/10.3390/md21070378 - 27 Jun 2023
Cited by 2 | Viewed by 1966
Abstract
Marine cyanobacteria are a rich source of bioactive natural products. Here, we report the isolation and structure elucidation of the previously reported iezoside (1) and its C-31 O-demethyl analogue, iezoside B (2), from a cyanobacterial assemblage collected at Loggerhead [...] Read more.
Marine cyanobacteria are a rich source of bioactive natural products. Here, we report the isolation and structure elucidation of the previously reported iezoside (1) and its C-31 O-demethyl analogue, iezoside B (2), from a cyanobacterial assemblage collected at Loggerhead Key in the Dry Tortugas, Florida. The two compounds have a unique skeleton comprised of a peptide, a polyketide and a modified sugar unit. The compounds were tested for cytotoxicity and effects on intracellular calcium. Both compounds exhibited cytotoxic activity with an IC50 of 1.5 and 3.0 μΜ, respectively, against A549 lung carcinoma epithelial cells and 1.0 and 2.4 μΜ against HeLa cervical cancer cells, respectively. In the same cell lines, compounds 1 and 2 show an increase in cytosolic calcium with approximate EC50 values of 0.3 and 0.6 μΜ in A549 cells and 0.1 and 0.5 μΜ, respectively, in HeLa cells, near the IC50 for cell viability, suggesting that the increase in cytosolic calcium is functionally related to the cytotoxicity of the compounds and consistent with their activity as SERCA (sarcoplasmic/endoplasmic reticulum Ca2+-ATPase) inhibitors. The structure–activity relationship provides evidence that structural changes in the sugar unit may be tolerated, and the activity is tunable. This finding has implications for future analogue synthesis and target interaction studies. Full article
(This article belongs to the Special Issue Bioactive Products from Marine Cyanobacteria and Their Potential Therapeutic Applications 2022)
►▼ Show Figures

Graphical abstract

13 pages, 562 KiB  
Article
New Nostocyclophanes from Nostoc linckia
by Jingqiu Dai, Casey S. Philbin, Clay Wakano, Wesley Y. Yoshida and Philip G. Williams
Mar. Drugs 2023, 21(2), 101; https://doi.org/10.3390/md21020101 - 31 Jan 2023
Cited by 5 | Viewed by 4483
Abstract
Six new nostocyclophanes and four known compounds have been isolated from Nostoc linckia (Nostocaceae) cyanobacterial strain UTEX B1932. The new compounds, nostocyclophanes E–J (1–6), were characterized by NMR and MS techniques. The known compounds were nostocyclophanes B–D, previously isolated [...] Read more.
Six new nostocyclophanes and four known compounds have been isolated from Nostoc linckia (Nostocaceae) cyanobacterial strain UTEX B1932. The new compounds, nostocyclophanes E–J (1–6), were characterized by NMR and MS techniques. The known compounds were nostocyclophanes B–D, previously isolated from this strain, and dedichloronostocyclophane D. Structural modifications on the new [7.7]paracyclophane analogs 1–5, isolated from the 80% methanol fraction, range from simple changes such as the lack of methylation or halogenation to more unusual modifications such as those seen in nostocyclophane H (4), in which the exocyclic alkyl chains are of different length; this is the first time this modification has been observed in this family of natural products. In addition, nostocyclophane J (6) is a linear analog in which C-20 is chlorinated in preparation for the presumed enzymatic Friedel–Craft cyclization needed to form the final ring structure, analogous to the biosynthesis of the related cylindrocyclophanes. Nostocyclophane D, dedichloronostocyclophane D, and nostocyclophanes E-J demonstrated moderate to weak growth inhibition against MDA-MB-231 breast cancer cells. Full article
(This article belongs to the Special Issue Bioactive Products from Marine Cyanobacteria and Their Potential Therapeutic Applications 2022)
►▼ Show Figures

Figure 1

13 pages, 2272 KiB  
Article
Identification of Anhydrodebromoaplysiatoxin as a Dichotomic Autophagy Inhibitor
by Limin Feng, Chung-Kuang Lu, Jiajun Wu, Leo Lai Chan and Jianbo Yue
Mar. Drugs 2023, 21(1), 46; https://doi.org/10.3390/md21010046 - 10 Jan 2023
Cited by 2 | Viewed by 2100
Abstract
Dysfunctional autophagy is associated with various human diseases, e.g., cancer. The discovery of small molecules modulating autophagy with therapeutic potential could be significant. To this end, we screened the ability of a series of metabolites isolated from marine microorganisms to modulate autophagy. Anhydrodebromoaplysiatoxin [...] Read more.
Dysfunctional autophagy is associated with various human diseases, e.g., cancer. The discovery of small molecules modulating autophagy with therapeutic potential could be significant. To this end, we screened the ability of a series of metabolites isolated from marine microorganisms to modulate autophagy. Anhydrodebromoaplysiatoxin (ADAT), a metabolite yielded by the marine red algae Gracilaria coronopifolia, inhibited autophagosome-lysosome fusion in mammalian cells, thereby inducing the accumulation of autophagosomes. Treatment of cells with ADAT alkalinized lysosomal pH. Interestingly, ADAT also activated the mTOR/p70S6K/FoxO3a signaling pathway, likely leading to the inhibition of autophagy induction. ADAT had little effect on apoptosis. Our results suggest that ADAT is a dichotomic autophagy inhibitor that inhibits both late-stage (autophagosome-lysosome fusion) and early-stage (autophagy induction) autophagy. Full article
(This article belongs to the Special Issue Bioactive Products from Marine Cyanobacteria and Their Potential Therapeutic Applications 2022)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop